Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company developing a pipeline of targeted prophylactic therapies for rare bleeding disorders. The company's lead programs include sutacimig for Glanzmann Thrombasthenia and HMB-002 for Von Willebrand Disease, alongside HMB-003 for heavy menstrual bleeding. Their research focuses on transitioning the standard of care from reactive bleed management to preventative treatment for patients with blood coagulation deficiencies.